Srinagar Magazine

The Polymyositis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Polymyositis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Polymyositis Market.

Some of the key takeaways from the Polymyositis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Polymyositis treatment therapies with a considerable amount of success over the years. 
• Polymyositis companies working in the treatment market are  JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, Viela Bio, Kezar Life Sciences Inc., Restem LLC, Bristol Myers Squib, and others, are developing therapies for the Polymyositis treatment 

• Emerging Polymyositis therapies such as – HuABC2, PF1801, PN-101, M5049, VIB7734, KZR-616, Umbilical Cord Lining Stem Cells, Abatacept, and others are expected to have a significant impact on the Polymyositis market in the coming years.   
• In January 2023, Merck KGaA Phase II a, randomized, parallel, double-blind, placebo controlled study to evaluate the efficacy and safety of Enpatoran in Dermatomyositis and Polymyositis participants receiving standard of care (NEPTUNIA)
• In September 2021, the US FDA granted Orphan Drug designation to PF1801 for the treatment of polymyositis
• In October 2020, the US FDA granted Orphan Drug Designations (ODD) for KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM)

Polymyositis Overview

Polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. Polymyositis (PM), an autoimmune disorder, develops due to abnormal activation of cytotoxic Tlymphocytes (CD8 cells) and macrophages against muscular antigens as well as the strong extrafusal muscular expression of major histocompatibility complex 1 causing damage to the endomysium of skeletal muscles.

Get a Free Sample PDF Report to know more about Polymyositis Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight

Emerging Polymyositis Drugs Under Different Phases of Clinical Development Include:

• HuABC2: JN Biosciences
• PF1801: ImmunoForge
• PN-101: Paean Biotechnology Inc.
• M5049: Merck KGaA
• VIB7734: Viela Bio
• Ustekinumab: Janssen Pharmaceutical
• KZR-616: Kezar Life Sciences Inc
• Umbilical Cord Lining Stem Cells: Restem LLC
• Abatacept: Bristol Myers Squibb

Route of Administration

Polymyositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Polymyositis Pipeline Therapeutics Assessment

• Polymyositis Assessment by Product Type
• Polymyositis By Stage and Product Type
• Polymyositis Assessment by Route of Administration
• Polymyositis By Stage and Route of Administration
• Polymyositis Assessment by Molecule Type
• Polymyositis by Stage and Molecule Type

DelveInsight’s Polymyositis Report covers around 7+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Polymyositis product details are provided in the report. Download the Polymyositis pipeline report to learn more about the emerging Polymyositis therapies

Some of the key companies in the Polymyositis Therapeutics Market include:

Key companies developing therapies for Polymyositis are – ytodyn,  ImmunoForge, Viela Bio, Paean Biotechnology, Kezar Life Sciences Inc, Bristol-Myers Squibb,  Janssen Pharmaceutical, Restem LLC and many others.

Polymyositis Pipeline Analysis:

The Polymyositis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Polymyositis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polymyositis Treatment.
• Polymyositis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Polymyositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polymyositis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Polymyositis drugs and therapies

Polymyositis Pipeline Market Drivers

• Growing cases of chronic muscle inflammation, continuous advancement in technology, increased injuries of muscle are some of the important factors that are fueling the Polymyositis Market.

Polymyositis Pipeline Market Barriers

• However, high cost of drugs, lack of approved therapies and other factors are creating obstacles in the Polymyositis Market growth.

Scope of Polymyositis Pipeline Drug Insight    

• Coverage: Global
• Key Polymyositis Companies: JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, Viela Bio, Kezar Life Sciences Inc., Restem LLC, Bristol Myers Squib, and others
• Key Polymyositis Therapies: HuABC2, PF1801, PN-101, M5049, VIB7734, KZR-616, Umbilical Cord Lining Stem Cells, Abatacept, and others
• Polymyositis Therapeutic Assessment: Polymyositis current marketed and Polymyositis emerging therapies
• Polymyositis Market Dynamics: Polymyositis market drivers and Polymyositis market barriers 

Request for Sample PDF Report for Polymyositis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services